11th International Forum on Rheumatoid Arthritis (IFRA)

The 11th International Forum on Rheumatoid Arthritis: Pathogenesis and Emerging Therapeutic Strategies (IFRA 2019) is designed to bring together leading rheumatologists from Europe, the United States and Asian countries working to better understand the pathogenesis and emerging therapeutic strategies in rheumatoid arthritis (RA). The field of rheumatology has made great advances in recent years through consortia-based efforts, including the Accelerating Medicines Partnership (AMP RA/SLE) and the Rheuma Tolerance for Cure (RTCure), as well as disease-focused groups such as the International Forum on Rheumatoid Arthritis (IFRA). Providing a joint congress for international leaders from each of these impactful partnerships to interact and collaborate is essential to harmonize strategic priorities, discuss prominent research datasets, and advance novel technologies at the RA frontier to move the field forward. Challenges in RA that remain unsolved include disease heterogeneity as well as uneven responsiveness to existing and novel treatment regimens. For promoting next-generation rheumatology, we must convene and construct global networks to best treat and serve our patients worldwide.

The Forum is scheduled for September 25th – 27th, 2019 and will be held in Washington, D.C. at the Washington Marriott at Metro Center.

View the draft agenda.

Partners

Public-Sector Partners:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)*

Sponsoring Consortia Partners:
Accelerating Medicines Partnership RA/SLE*
Innovative Medicines Initiative*
International Forum for Rheumatoid Arthritis*
Rheuma Tolerance for Cure (RTCure)*

*provides financial or in-kind support for this program.

Accelerating Medicines Partnership (AMP)
AMP Overview
NIAMS AMP RA/SLE
FNIH AMP RA/SLE
ImmPort Data Portal

Innovative Medicines Initiative (IMI) and Rheuma Tolerance for Cure (RTCure)
www.rtcure.com
www.imi.europa.eu
RT Cure Factsheet

International Forum for Rheumatoid Arthritis (IFRA)
Japan College of Rheumatology
APLAR

National Institute of Arthritis and Musculoskeletal and Skin Diseases
www.niams.nih.gov
www.nih.gov

FNIH Contact

Steve Hoffmann, Director, Inflammation and Immunity, shoffmann@fnih.org